SCHEMBL4059567

SCHEMBL4059567

O=c1[nH]cc(-c2ccccc2)n1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
HPGD P15428 4/20 0.52
KDM4E B2RXH2 2/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.49
RAD51 Q06609 1/20 0.48
RPA1 P27694 2/20 0.47
GAA P10253 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MAPK1 P28482 1/20 0.42
TSHR P16473 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053051 0.83 ALDH1A1 (0.60) ALDH1A1HPGDKDM4ELMNAGAA
SCHEMBL4232792 0.80 ALDH1A1 (0.65) ALDH1A1HPGDKDM4ELMNAGAA
SCHEMBL11126289 0.76 ALDH1A1 (0.69) ALDH1A1HPGDKDM4ELMNAGAA
SCHEMBL11123802 0.76 MAPK1 (0.69) ALDH1A1HPGDKDM4ELMNAGAA
SCHEMBL11125616 0.76 ALDH1A1 (0.51) ALDH1A1HPGDKDM4ELMNAGAA
SCHEMBL11124324 0.73 KMT2A (0.52) ALDH1A1HPGDLMNARPA1GAA
SCHEMBL4093082 0.72 CYP1A2 (0.51) ALDH1A1HPGDKDM4ELMNATP53
SCHEMBL5755545 0.71 HPGD (0.48) ALDH1A1HPGDKDM4ELMNATP53
SCHEMBL11608487 0.71 TP53 (0.53) ALDH1A1KDM4ETP53RAD51GAA
SCHEMBL31576799 0.68 TP53 (0.49) ALDH1A1LMNATP53RAD51MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553862-B2 4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones HOFFMANN-LA ROCHE INC. (US) 2009-06-30 US disclosed
US-7553862-B2 4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones HOFFMANN-LA ROCHE INC. (US) 2009-06-30 US disclosed
US-7553862-B2 4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones HOFFMANN-LA ROCHE INC. (US) 2009-06-30 US disclosed
WO-2007101802-A1 4-AMINO-1,5-SUBSTITUTED 1,5-DIHYDRO-IMIDAZOL-2-ONES F. HOFFMANN-LA ROCHE AG (CH) 2007-09-13 WO disclosed
US-20070213384-A1 4-Amino-1,5-substituted-1,5-dihydro-imidazol-2-ones F. HOFFMANN-LA ROCHE AG (CH) 2007-09-13 US disclosed
US-20070213384-A1 4-Amino-1,5-substituted-1,5-dihydro-imidazol-2-ones F. HOFFMANN-LA ROCHE AG (CH) 2007-09-13 US disclosed
US-20070213384-A1 4-Amino-1,5-substituted-1,5-dihydro-imidazol-2-ones F. HOFFMANN-LA ROCHE AG (CH) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213384-A1 4-Amino-1,5-substituted-1,5-dihydro-imidazol-2-ones SLC1A2, SLC6A5, SLC1A1 ALDH1A1 697/4885HPGD 2553/4885KDM4E 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.